China Universal Asset Management Co. Ltd. Increases Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

China Universal Asset Management Co. Ltd. lifted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 3.9% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 25,629 shares of the biopharmaceutical company's stock after buying an additional 955 shares during the period. Regeneron Pharmaceuticals makes up approximately 1.5% of China Universal Asset Management Co. Ltd.'s investment portfolio, making the stock its 12th biggest holding. China Universal Asset Management Co. Ltd.'s holdings in Regeneron Pharmaceuticals were worth $16,255,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Capital International Investors lifted its position in Regeneron Pharmaceuticals by 41.6% during the fourth quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock valued at $3,373,859,000 after purchasing an additional 1,390,534 shares during the period. Norges Bank acquired a new position in Regeneron Pharmaceuticals during the fourth quarter valued at $802,036,000. GAMMA Investing LLC lifted its position in Regeneron Pharmaceuticals by 89,825.0% during the first quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock valued at $517,291,000 after purchasing an additional 814,713 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in Regeneron Pharmaceuticals by 63.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company's stock valued at $1,485,527,000 after buying an additional 810,144 shares in the last quarter. Finally, Loomis Sayles & Co. L P boosted its stake in shares of Regeneron Pharmaceuticals by 33.4% during the 4th quarter. Loomis Sayles & Co. L P now owns 1,575,349 shares of the biopharmaceutical company's stock worth $1,122,168,000 after acquiring an additional 393,997 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on REGN shares. Wells Fargo & Company cut Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and dropped their target price for the company from $700.00 to $580.00 in a research report on Friday, May 30th. Citigroup dropped their target price on Regeneron Pharmaceuticals from $700.00 to $650.00 and set a "buy" rating on the stock in a research report on Monday, June 2nd. Argus cut Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Monday, June 30th. Royal Bank Of Canada cut Regeneron Pharmaceuticals from a "moderate buy" rating to a "hold" rating and set a $662.00 price objective on the stock. in a report on Friday, May 30th. Finally, Canaccord Genuity Group raised Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, April 22nd. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $822.54.

Regeneron Pharmaceuticals Trading Up 1.3%

Shares of Regeneron Pharmaceuticals stock traded up $7.18 on Thursday, reaching $559.76. The company had a trading volume of 827,335 shares, compared to its average volume of 911,489. The firm's 50 day moving average price is $546.58 and its two-hundred day moving average price is $622.59. The firm has a market cap of $60.43 billion, a PE ratio of 14.25, a PEG ratio of 2.02 and a beta of 0.33. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.03 and a current ratio of 4.93.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The company had revenue of $3.03 billion during the quarter, compared to analysts' expectations of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. Regeneron Pharmaceuticals's revenue was down 3.7% on a year-over-year basis. During the same period last year, the firm posted $9.55 earnings per share. Sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.63%. The ex-dividend date was Tuesday, May 20th. Regeneron Pharmaceuticals's payout ratio is currently 8.96%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.